Aktis Oncology priced an initial public offering that raised about $318 million, marking the first US biotech IPO of 2026 and signaling renewed public‑market appetite for radiopharmaceuticals. The Boston‑based company said the proceeds will support development of its miniprotein radioconjugates, including lead candidate AKY‑1189 targeting Nectin‑4 and second asset AKY‑2519 aimed at B7‑H3–expressing tumors. Eli Lilly participated as a $100 million anchor investor, taking roughly one‑third of the float and underscoring strategic pharma interest in targeted radiotherapeutics. Aktis said it will report Phase 1 data for AKY‑1189 in early 2027 and highlighted prior private financings that totaled about $346 million. The IPO positioned Aktis among a handful of radiopharma companies that have drawn Big Pharma partnerships and investor enthusiasm after recent regulatory and commercial wins in the space.